9
Apr 2026
Tulane study shows team approach improves hypertension treatment success
High blood pressure is treatable through medications and lifestyle changes but remains a leading cause of death in the United States.








We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
With tailor-made research projects, we provide insights into what works, for whom, at what cost, and under what circumstances to achieve objectives, such as improved healthcare quality, health outcomes, efficiency and staff satisfaction, we support our clients in making evidence-based decisions.
The process of bringing your healthcare innovation to the market is lengthy and complicated. Besides the clinical or humanistic value that your product generates, for example by decreasing complication rate, prolonging survival, improving patient flow, the economic value needs to be demonstrated to healthcare payers.
We help you prepare yourself for (future) discussions with stakeholders about your innovations. During a 1,5 h discussion, we advise you on how to collect, analyse and present data.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
9
Apr 2026
High blood pressure is treatable through medications and lifestyle changes but remains a leading cause of death in the United States.
READ MORE
9
Apr 2026
A Mount Sinai ophthalmologist will unveil a novel surgical technology that allows eye surgeons to measure and respond to critical fluid dynamics inside the eye in real time—an advance that may significantly improve precision and outcomes in glaucoma and other ophthalmic procedures.
READ MORE
9
Apr 2026
Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas—blood cancers that arise in immune cells called B cells—yet the same is not true for patients with more rare lymphoma types that originate in immune cells called T cells.
READ MORE
9
Apr 2026
Better cancer care depends on better treatment options. That's why the Ontario Institute for Cancer Research (OICR) is supporting four Ontario-based research teams working to develop the next generation of cancer therapies that are designed to be more effective at destroying tumors, have reduced side effects, and make cancer less likely to return.
READ MORE